Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2007

View Archived Issues

Recent patents describe new treatments for ADHD, depression and anxiety

Tarantula-derived peptide shows analgesic effects via ASIC blockade and activation of opioid system

Squalestatin protects neurons in culture from Abeta toxicity

Janssen-Cilag submits MAA for ceftobiprole to Swissmedic

Potential disease-modifying anti-AD drugs discovered under a Wyeth/ArQule collaboration

Series of nonsteroidal SARMs discovered at GSK

Potent and selective PPARalpha activator emerges from SAR program at BMS

Patient enrollment in phase III trial of QUATRx's Ophena completed

Systems Medicine and NCI enter cancer R&D agreement

Thallion completes phase I/II trial of ECO-4601 for advanced cancer

Vical reports results from a series of pDNA vaccine phase IIa trials for HIV

Teijin and Chugai agree to codevelop Ipsen's antidiabetic medicine in Japan

Enrollment for Medidur human PK study commences

Med Discovery and Draximage embark on research collaboration

New treatments for gynecological disorders disclosed in recent Lilly patent

Roche's Avastin approved in E.U. for first-line treatment of NSCLC patients

MHLW approves additional dosage and administration for PPIs

Cephalon acquires North American rights to Amrix from ECR

First patients enrolled in AtheroGenics phase III diabetes trial of AGI-1067

FDA approves Risperdal for schizophrenia and short-term bipolar mania in adolescents

Regeneron and sanofi-aventis begin phase III aflibercept oncology program

AstraZeneca begins phase IIb trial of AZD-3480 for schizophrenia

Novartis' Rasilez approved in the E.U. for high blood pressure

Novel SARMs designed by Merck as potential osteoanabolic agents

New class of small-molecule MCH-R1 antagonists reported by Schering-Plough

Dual CRTH2/DP receptor antagonist selected as development candidate at Amgen

Schering-Plough synthesizes and characterizes novel NK1 antagonists for emesis

BMS continues to search for improved IGF-1R kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...